MedTrace Logo

The Intra-Drug Eluting Stent (DES) Restenosis Study

NCT00323895 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2010-07-29

No results posted yet for this study

Summary

A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.

Conditions

Interventions

DEVICE

drug-eluting stent and balloon angioplasty

CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand

DEVICE

drug-eluting stent and balloon angioplasty

CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand

DEVICE

drug-eluting stent

CYPHER Select ™ Sirolimus-eluting Stent

Sponsors & Collaborators

  • Cordis Corporation

    lead INDUSTRY

Principal Investigators

  • Bernard Chevalier, MD · Centre Cardiologique du Nord, Saint Denis, France

  • Jean Fajadet, MD, PhD · Unité de Cardiologie Interventionnelle, Toulouse Cedex 3, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323895 on ClinicalTrials.gov